Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study to Evaluate the Efficacy and Safety of Vismodegib in Combination With Ruxolitinib for the Treatment of Intermediate- or High-Risk Myelofibrosis (MF)

Phase 1

Completed

Conditions: Myelofibrosis

Interventions: Other: Placebo
Drug: Ruxolitinib
Drug: Vismodegib

First Posted Date: 2015-11-01

Last Posted Date: 2018-05-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 10

Registration Number: NCT02593760

Locations: 🇺🇸
Florida Cancer Specialists, West Palm Beach, Florida, United States
🇺🇸
Oncology Hematology Care Inc, Cincinnati, Ohio, United States
🇺🇸
Florida Cancer Specialists-Broadway, Fort Myers, Fort Myers, Florida, United States

and more 10 locations

An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients.

Completed

Conditions: Rheumatoid Arthritis

Interventions: Other: Routine clinical practice

First Posted Date: 2015-10-29

Last Posted Date: 2017-08-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 808

Registration Number: NCT02590562

Locations: 🇨🇳
China-Janpan Friendship Hospital of Jilin University, Changchun, China
🇨🇳
Beijing Jishutan Hospital; Rheumatology & Immunology, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, China

and more 12 locations

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

Phase 1

Completed

Conditions: Kidney Failure, Chronic

Interventions: Drug: Obinutuzumab
Drug: Intravenous Immunoglobulin

First Posted Date: 2015-10-26

Last Posted Date: 2020-01-29

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 24

Registration Number: NCT02586051

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
UCSF, San Francisco, California, United States
🇺🇸
Mayo Clinic - Minnesota, Rochester, Minnesota, United States

and more 6 locations

Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive Breast Cancer to Evaluate Treatment With Trastuzumab Plus (+) Pertuzumab + Docetaxel Compared With Trastuzumab + Placebo + Docetaxel

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: FEC Chemotherapy
Procedure: Surgery
Drug: Docetaxel
Drug: Placebo
Drug: Pertuzumab
Drug: Trastuzumab

First Posted Date: 2015-10-26

Last Posted Date: 2023-05-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 329

Registration Number: NCT02586025

Locations: 🇨🇳
Taipei Medical University ?Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳
China Medical University Hospital; Surgery, Taichung, Taiwan
🇹🇭
Bhumibol Adulyadej Hospital; Medicine, Bangkok, Thailand

and more 20 locations

A Study of Capecitabine (Xeloda) in the Adjuvant Treatment of Participants With Resected Colon Cancer

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2015-10-21

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 63

Registration Number: NCT02581423

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum

Phase 4

Completed

Conditions: Colorectal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Bevacizumab
Drug: Irinotecan
Drug: Oxaliplatin

First Posted Date: 2015-10-21

Last Posted Date: 2017-03-09

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 40

Registration Number: NCT02582970

A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Enfuvirtide

First Posted Date: 2015-10-21

Last Posted Date: 2016-07-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 23

Registration Number: NCT02582983

Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples

Completed

Conditions: Breast Cancer

First Posted Date: 2015-10-20

Last Posted Date: 2016-02-22

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 30

Registration Number: NCT02580799

Locations: 🇹🇷
Istanbul University Istanbul Medical Faculty, Istanbul, Turkey
🇹🇷
Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey
🇹🇷
Ankara University Medical Faculty, Ankara, Turkey

and more 2 locations

A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Capecitabine
Drug: Peginterferon alfa-2a

First Posted Date: 2015-10-15

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 16

Registration Number: NCT02576964

A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)

Phase 4

Completed

Conditions: Kidney Transplantation

Interventions: Biological: DT
Drug: Daclizumab
Biological: KLH

First Posted Date: 2015-10-15

Last Posted Date: 2016-01-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 11

Registration Number: NCT02576145

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy